Variables

Patients with   LDH<246
Group 1     

N=102%

Patients with LDH≥246 
Group 2

N=54%

Total  (156)

N%

Median age
years (min-max)

26.5 (13-57)

25.5 (15-52)

26.0 (13-57)

Gender
female
male

42 (41.2)
60 (58.8)

21 (38.9)
33 (61.1)

63 (40.3)
93 (59.7)

Diagnosis
AML
ALL
CML
AA
Lymphoma
Others

43 (42.2)
25 (24.5)
4 (3.9)
14 (13.7)
10 (9.8)
6 (5.9)

23 (42.6)
13 (24.1)
2 (3.7)
4 (7.4)
6 (11.1)
6 (11.1)

68(43.5)
38 (24.3)
6 (3.8)
18 (11.5)
16 (10.3)
12 (7.6)

Acute GVHD
Yes
No

20(19.6)
82(80.4)

13(24.1)
41(75.9)

33(21.1)
123(78.9)

Chronic GVHD
Yes
No

38(37.3)
64(62.7)

20(37.0)
34(63.0)

58(37.1)
98(62.9)

Disease status at tx
CR1
CR2
Active disease

90(88.3)
4(3.9)
8(7.8)

45(83.3)
3(5.6)
6(11.1)

135(86.5)
7(4.6)
14(8.9)

 CD34⁺ (10⁶/kg)

Preparative regimen
Bu/Cy
TBI/Cy
ATG/Flu/Cy
ATG/Flu/Bu
Flu/Cy
Others

52(51.0)
14(13.7)
12(11.8)
3(2.9)
9(8.8)
12(11.8)

25(46.3)
7(13.0)
4(7.4)
6(11.1)
3(5.6)
9(7.6)

77(49.3)
21(13.5)
16(10.3)
9(5.7)
12(7.7)
21(13.5)

HLA match
full-match
≥ 1 miss-match
Unrelated

90(88.2)
11(10.8)
1(1.0)

44(81.5)
8(14.8)
2(3.7)

134(85.9)
19(12.1)
3(2.0)

Median interval to tx (months)
<12 months
>12 months

69(67.6)
33(32.4)

37(68.5)
17(31.5)

106(78.0)
50(22.0)

Graft source
PBSC
BM

102 (100)
0

54 (100)
0

156(100)
0

Gender match
matched
mismatched

76(74.5)
26(25.5)

35(64.8)
19(35.2)

111(71.1)
45(28.9)